Table 1.
Uncorrected cohort characteristics.
| INJ (n = 150) | DMF (n = 254) | TER (n = 83) | FGD (n = 92) | p-Value | |
|---|---|---|---|---|---|
| Females, n (%) | 118 (78.7) | 183 (72.0) | 68 (81.9) | 67 (72.8) | 0.113 |
| Age, mean (SD) | 41.6 (13.1) | 44.7 (12.2) | 49.4 (10.4) | 39.8 (9.3) | <0.001 |
| Caucasian, n (%) | 120 (80.0) | 216 (85.0) | 70 (84.3) | 71 (77.2) | 0.020 |
| MS duration, years, mean (SD) | 5.4 (8.2) | 10.6 (9.4) | 12.2 (9.8) | 7.1 (6.9) | <0.001 |
| Follow-up duration, months, mean (SD) | 18.2 (7.7) | 20.4 (6.5) | 20.3 (7.2) | 17.2 (7.2) | 0.015 |
| Number of previous meds, n (%) | |||||
| 0 | 77 (51.3) | 33 (13.0) | 4 (4.8) | 11 (12.0) | <0.001 |
| 1 | 33 (22.0) | 75 (30.0) | 40 (48.2) | 34 (37.0) | |
| 2 | 25 (16.7) | 73 (28.7) | 23 (27.7) | 25 (27.2) | |
| 3+ | 15 (10.0) | 73 (28.7) | 16 (19.3) | 22 (23.9) | |
| Physician, n (%) | |||||
| 1 | 27 (18.0) | 24 (9.5) | 6 (7.2) | 14 (15.2) | <0.001 |
| 2 | 38 (25.3) | 58 (22.8) | 17 (20.5) | 7 (7.6) | |
| 3 | 19 (12.7) | 33 (13.0) | 38 (45.8) | 33 (26.8) | |
| 4 | 19 (12.7) | 23 (9.1) | 3 (3.6) | 7 (7.6) | |
| 5 | 47 (31.3) | 116 (45.7) | 19 (22.9) | 31 (33.7) | |
| Disability | |||||
| Mild (EDSS 0-3) | 110 (73.3) | 143 (56.3) | 43 (51.8) | 52 (56.5) | <0.001 |
| Moderate (EDSS 3.5-5.5) | 29 (19.3) | 46 (18.11) | 19 (22.9) | 30 (32.6) | |
| Severe (EDSS ≥ 6.0) | 11 (7.3) | 65 (25.6) | 21 (25.3) | 10 (10.9) | |
| Relapses in last 12 months, n (%) | 92 (61.3) | 112 (44.1) | 27 (32.5) | 46 (50.0) | <0.001 |
| On-drug MS activity, n (%) | 28 (18.7) | 54 (21.3) | 25 (30.1) | 24 (26.1) | 0.144 |
| Discontinued DMT, n (%) | 58 (38.7) | 90 (35.4) | 38 (45.8) | 30 (32.6) | 0.167 |
| Switched to a different DMT | 46 (79.3) | 74 (82.2) | 31 (81.6) | 24 (80.0) | |
| Permanently discontinued | 12 (20.7) | 15 (16.7) | 6 (15.8) | 6 (20.0) | |
| Death | 0 | 1 (1.1) | 1 (2.6) | 0 |
DMF: dimethyl fumarate; DMT: disease-modifying therapy; EDSS: estimated disability status score; FGD: fingolimod; INJ: injectable; MS: multiple sclerosis; SD: standard deviation; TER: teriflunomide.
A total of 480 unique patients contributed 579 observations to this cohort. Repeated observations were not considered for the statistics reported. One-way analysis of variance (ANOVA) was used to compare age, disease duration, and follow-up duration between groups. Pearson chi-square tests were used to compare sex, race, MS activity, discontinued DMT, and number of prior medications between groups. One patient in the DMF group and one in the TER group died due to comorbid medical conditions; deaths were unrelated to MS treatment.